Literature DB >> 11460589

Pathogenesis of diabetic nephropathy.

A E Raptis1, G Viberti.   

Abstract

Diabetic Nephropathy (DN) is the commonest cause of end-stage renal failure (ESRF) in the Western world. Diabetic nephropathy follows a well outline clinical course, starting with microalbuminuria through proteinuria, azotaemia and culminating in ESRF. Before the onset of overt proteinuria, there are various renal functional changes including renal hyperfiltration, hyperperfusion, and increasing capillary permeability to macromolecules. Basement-membrane thickening and mesangial expansion have long been recognized as pathological hallmark of diabetes. It has been postulated that DN occurs as a result of the interplay of metabolic and hemodynamic factors in the renal microcirculation. There is no doubt that there is a positive relationship between hyperglycaemia, which is necessary but not sufficient, and microvascular complications. The accumulation of advanced glycosylated end-products (AGEs), the activation of isoform(s) of protein kinase C (PKC) and the acceleration of the aldose reductase pathway may explain how hyperglycemia damages tissue. PKC is one of the key signaling molecules in the induction of the vascular pathology of diabetes. The balance between extracellular matrix production and degradation is important in this context. Transforming growth factor-beta (TGF-beta) appears to play a pivotal role in accumulation in the diabetic kidney. Hemodynamic disturbances are believed to be directly responsible for the development of glomerulosclerosis and its attendant proteinuria. There is familial clustering of diabetic kidney disease. A number of gene loci have been investigated to try to explain the genetic susceptibility to diabetic nephropathy. The genes coding for components of renin-angiotensin system have drawn special attention, due to the central role that this system plays in the regulation of blood pressure, sodium metabolism, and renal hemodynamics. Endothelial dysfunction is closely associated with the development of diabetic retinopathy, nephropathy and atherosclerosis, both in IDDM and in NIDDM. The pathogenesis of diabetic nephropathy is not clarified completely yet.

Entities:  

Mesh:

Year:  2001        PMID: 11460589     DOI: 10.1055/s-2001-18600

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  64 in total

1.  The effects of anti-inflammatory and anti-angiogenic DNA vaccination on diabetic nephropathy in rats.

Authors:  Peter Celec; Július Hodosy; Roman Gardlík; Michal Behuliak; Roland Pálffy; Marek Pribula; Peter Jáni; Ján Turňa; Katarína Sebeková
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

2.  Preparation and characterization of polyclonal antibodies against ARL-1 protein.

Authors:  Jun-Fei Jin; Liu-Di Yuan; Li Liu; Zhu-Jiang Zhao; Wei Xie
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

3.  Effects of the diabetes linked TCF7L2 polymorphism in a representative older population.

Authors:  David Melzer; Anna Murray; Alison J Hurst; Michael N Weedon; Stefania Bandinelli; Anna Maria Corsi; Luigi Ferrucci; Guiseppe Paolisso; Jack M Guralnik; Timothy M Frayling
Journal:  BMC Med       Date:  2006-12-20       Impact factor: 8.775

4.  Reduced beta 2 glycoprotein I improves diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathway.

Authors:  Tong Wang; Si-Si Chen; Rui Chen; De-Min Yu; Pei Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

5.  Diagnostic value of quantitative contrast-enhanced ultrasound (CEUS) for early detection of renal hyperperfusion in diabetic kidney disease.

Authors:  Ling Wang; Jian Wu; Jia-Fen Cheng; Xin-Ying Liu; Fang Ma; Le-Hang Guo; Jun-Mei Xu; Tianfu Wu; Chandra Mohan; Ai Peng; Hui-Xiong Xu; Ya-Xiang Song
Journal:  J Nephrol       Date:  2015-02-25       Impact factor: 3.902

6.  Management of Diabetic Nephropathy in the Elderly: Special Considerations.

Authors:  Emaad M Abdel-Rahman; Tarek Alhamad; W Brian Reeves; Alaa S Awad
Journal:  J Nephrol Ther       Date:  2012-10

7.  The relationship of retinal vessel diameter to changes in diabetic nephropathy structural variables in patients with type 1 diabetes.

Authors:  R Klein; M D Knudtson; B E K Klein; B Zinman; R Gardiner; S Suissa; A R Sinaiko; S M Donnelly; P Goodyer; T Strand; M Mauer
Journal:  Diabetologia       Date:  2010-05-01       Impact factor: 10.122

8.  The role of vascular endothelial growth factor +405 G/C polymorphism and albuminuria in patients with type 2 diabetes mellitus.

Authors:  Abdolrahim Nikzamir; Alireza Esteghamati; Amir Abbas Hammedian; Touraj Mahmoudi
Journal:  Mol Biol Rep       Date:  2011-05-12       Impact factor: 2.316

9.  Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats.

Authors:  Joong Kyung Sung; Jang Hyun Koh; Mi Young Lee; Bo Hwan Kim; Soo Min Nam; Jae Hyun Kim; Jin Hee Yoo; So Hee Kim; Sun Won Hong; Eun Young Lee; Ran Choi; Choon Hee Chung
Journal:  Yonsei Med J       Date:  2010-05       Impact factor: 2.759

10.  The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat.

Authors:  Carolyn M Ecelbarger; Arjun Rash; Rajesh K Sinha; Swasti Tiwari
Journal:  Mediators Inflamm       Date:  2010-05-17       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.